Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating human papillomavirus vaccination programs.

Al V Taira1, Christopher P Neukermans, Gillian D Sanders

  • 1Stanford School of Medicine, Stanford, California, USA.

Emerging Infectious Diseases
|November 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical phenotypes and outcomes associated with improved left ventricular ejection fraction after biventricular pacing.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2025
Same author

Cardiac Resynchronization Therapy in Ischemic Versus Nonischemic Cardiomyopathy: Patient-Level Meta-Analysis of 7 Randomized Clinical Trials.

JACC. Heart failure·2024
Same author

Outcomes of Cardiac Resynchronization Therapy by New York Heart Association Class: A Patient-Level Meta-Analysis.

Journal of the American Heart Association·2024
Same author

Relationship between sex, body size, and cardiac resynchronization therapy benefit: A patient-level meta-analysis of randomized controlled trials.

Heart rhythm·2024
Same author

Benefit of cardiac resynchronization therapy among older patients: A patient-level meta-analysis.

American heart journal·2023
Same author

Comorbidities and clinical response to cardiac resynchronization therapy: Patient-level meta-analysis from eight clinical trials.

European journal of heart failure·2023
Same journal

Detection of and Early Genomic Insights into Chikungunya Virus, Bolivia, 2025.

Emerging infectious diseases·2026
Same journal

Household Transmission of Enterovirus D68, Washington and Oregon, United States, 2022-2024.

Emerging infectious diseases·2026
Same journal

New World Ocular Dirofilariasis Caused by Dirofilaria repens Infection, United States.

Emerging infectious diseases·2026
Same journal

Angiostrongylus cantonensis Rat Lungworm Detected in Rats, Madagascar, 2022-2023.

Emerging infectious diseases·2026
Same journal

Human Pulmonary Dirofilariasis,
North Queensland, Australia, 2023<sup>1</sup>.

Emerging infectious diseases·2026
Same journal

Trends in Congenital Syphilis Cases by Maternal Country of Birth, Spain, 2016-2024.

Emerging infectious diseases·2026
See all related articles

Vaccinating 12-year-old girls against human papillomavirus (HPV) types 16 and 18 significantly reduces cervical cancer cases. Including boys in the HPV vaccine program offers minimal additional benefit for cervical cancer prevention and is less cost-effective.

Area of Science:

  • Epidemiology
  • Public Health
  • Vaccinology

Background:

  • Human papillomavirus (HPV) is the primary cause of cervical cancer.
  • High-risk HPV types, specifically HPV-16 and HPV-18, are responsible for a majority of cervical cancer cases.
  • Vaccines targeting HPV-16 and HPV-18 are undergoing clinical evaluation.

Purpose of the Study:

  • To evaluate the impact and cost-effectiveness of HPV-16/18 vaccination programs.
  • To model HPV prevalence and infection rates across different demographic and behavioral groups.
  • To compare the outcomes of female-only vaccination versus including male participants.

Main Methods:

  • Development of disease transmission models to estimate HPV prevalence and infection.
  • Inclusion of data from clinical trials and published/unpublished sources.

Related Experiment Videos

  • Analysis of vaccination scenarios for 12-year-old girls and combined male/female cohorts.

    • Main Results:

    • A female-only HPV-16/18 vaccination program for 12-year-olds could decrease cervical cancer cases by 61.8%.
    • The cost-effectiveness ratio for female-only vaccination was estimated at $14,583 per quality-adjusted life year (QALY).
    • Including males in the vaccine rollout yielded a marginal 2.2% additional reduction in cervical cancer cases at a significantly higher incremental cost-effectiveness ratio ($442,039/QALY).

    Conclusions:

    • HPV-16 and HPV-18 vaccination programs can be a cost-effective strategy for cervical cancer prevention.
    • Female-only vaccination is generally more cost-effective than programs including male participants.
    • Targeting vaccination efforts towards females demonstrates a favorable balance of clinical benefit and economic efficiency.